Arrowhead Reports Positive Phase 3 Results for Plozasiran in sHTG Trials

Key Facts

In a move reflecting significant progress in biotech treatments for metabolic disorders, Arrowhead Pharmaceuticals has announced positive topline results from its Phase 3 clinical trials of plozasiran. According to reports, the SHASTA-3 and SHASTA-4 studies successfully met their primary endpoints by demonstrating a reduction in triglyceride levels among patients with severe hypertriglyceridemia (sHTG). This development is critical as the drug aims to mitigate the risk of acute pancreatitis in affected individuals.

The successful Phase 3 data represents a major regulatory milestone for the firm, potentially accelerating the path toward commercialization. Based on the analyst facts, the trials focused on the efficacy of plozasiran in managing complex lipid profiles, strengthening the company's position within the pharmaceutical sector. These results, though sourced from corporate communications, provide a bullish outlook for the company's clinical pipeline.

In the equity markets, ARWR stood at $74.52 (close July 21, 2026), having traded within a range of $72.62 to $74.7 during the session. Investors should monitor broader market catalysts, including the upcoming U.S. Retail Sales and Initial Jobless Claims data scheduled for July 16, which may influence sentiment across the healthcare and biotechnology sectors.